Histogen Inc. (NASDAQ:HSTO) traded at $1.98 at last check on Wednesday, Sep 16, making an upward move of 21.47% on its previous day’s price.
Looking at the stock we see that its previous close was $1.63 and the beta (5Y monthly) reads 1.58 with the day’s price range being $1.6700 – 2.1200. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, HSTO has a high of $7.5 and a low of $1.61. The company’s stock has gained about -36.33% over that past 30 days.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $526Million, with a low of $1.65 Million and a high of $1.65 Million. The median projection represents growth adding up to -92.9% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $21.72 Million, or -35.3% down from figures reported last year.
On the other hand, looking at the outlook for the HSTO stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 1 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Histogen Inc. (HSTO) stock as a Hold, while none rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the HSTO stock currently stands at 0, and the current price level is 3.8% off its SMA20 and -21.47% from its 50-day simple moving average. The RSI (14) is pointing at 45.8 while the volatility over the past week is 7.05% and jumps to 8.78% over the past one month. The beta value is 1.58, while the average true range (ATR) is currently pointing at 0.18. The average price target for the stock over the next 12 months is $15, with the estimates having a low of $15 and a high of $15. These price ends are 657.58% and +657.58% off the current price level respectively, although investors could be excited at the prospect of a +657.58% if the HSTO share price touches on the median price of $15.
Let’s briefly compare Histogen (HSTO) stock to its peers. We find that today’s price change of +21.47% and -57.76% over the past 12 months for HSTO competes that of Abbott Laboratories (ABT), which has seen its stock price rise 0.31% in the latest trading session and is +27.86% over the last one year. Another of its peers Medtronic Inc (MDT) has climbed 0.54% today, but is -1.36% down over the past year, while Stryker Corp (SYK) is also up 21.47% yet its price remains in the red at -57.76% over the same period. Abbott has a P/E ratio of 61.64 compared to Histogen’s 0 and Medtronic’s 33.19. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.56% and 0.78%, respectively, in early deals.
Coming back to Histogen Inc. (NASDAQ:HSTO), we note that the average 3-month trading volume was 55.9 Million, while that of the preceding 10-day period stands at 38.23 Million. Current shares outstanding are 12.21 Million.